Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Original Denis Brawn Brace Versus Its Modification for Management of Relapsed Idiopathic Clubfoot Following Ponseti Casting

NCT07125794 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-05-01
Last updated
2025-08-15

Condition(s) studied

Denis Brawn BraceModificationManagementIdiopathic ClubfootPonseti Casting

Investigational drug(s) / intervention(s)

Original Denis Browne splintModified Denis Browne splint

Original Denis Browne splint: Patients who were managed with the original Denis Browne splint.

Modified Denis Browne splint: Patients who were managed with the modified Denis Browne splint.

Study summary

This study aims to compare the effectiveness of the original Denis Brawn brace to its modification in managing relapsed idiopathic clubfoot in patients following Ponseti casting.

Eligibility

Sex
ALL
Min age
2 Years
Max age
5 Years
Healthy volunteers
No
Inclusion Criteria: * Age from 2 to 5 years. * Both sexes. * Relapsed cases. * Patients with idiopathic clubfoot. Exclusion Criteria: * Neurological or syndromic involvement. * Presenting with skin or soft-tissue lesions around the foot and ankle. * Inadequate documentation. * Soft-tissue surgery is needed (except tendo-achilles tenotomy). * Irregular plaster casting schedule.

Primary outcome measure(s)

  • Parents' compliance — 12 months post-procedure
    Parents' compliance will be classified into three grades as follows: * Grade 0: poor follow-up with a lack of commitment in bracing hours (bad compliance). * Grade 1: an intermittent follow-up with a good commitment in bracing hours (intermediate compliance). * Grade 2: a good follow-up with a strict commitment in bracing hours (good compliance).

Trial sites (1)

FacilityCityRegionStatus
General Authority for Teaching Hospitals and Institutes Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07125794 on ClinicalTrials.gov ↗ ← All trials in Egypt